¿ÞÂÊ ¸Þ´º ŸÀÌƲ À̹ÌÁö
°øÁö»çÇ×

Home < ¿­¸°¸¶´ç < °øÁö»çÇ×

       2012 È£¾Ï ÀÇÇлó ¼ö»óÀÚ(Á¤Àç¿õ ¹Ú»ç) ±â³ä °­¿¬È¸ °³ÃÖ ¾È³»
               
       biodesign        2012.04.30 16:51        5533
 
1. ¼ö»óÀÚ/°­¿¬ÀÚ: Á¤Àç¿õ ¹Ú»ç (Ú¸ ³²°¡ÁÖ´ë KECK ÀÇ´ë ±³¼ö, KAIST »ý¸í°úÇаú °âÀÓ±³¼ö) 2. ÀϽÃ: 2012. 5. 2 (¼ö) ¿ÀÈÄ 4½Ã 3. Àå¼Ò: KAIST KIºôµù(E4) 1Ãþ Ç»ÀüȦ 4. ÁÖÃÖ: KAIST »ý¸í°úÇаú, KI ¹ÙÀÌ¿ÀÀ¶ÇÕ¿¬±¸¼Ò, ISBC ±Û·Î¹úÇÁ·ÐƼ¾î ¿¬±¸´Ü, KAIST-USC ±Û·Î¹ú¿¬±¸¼Ò, È£¾ÏÀç´Ü * °­¿¬ Á¦¸ñ ¹× ÃÊ·Ï Host-Pathogen Standoff: Roles of Pattern Recognizing Receptors and Intracellular Restriction Factors in Antiviral Immune Response Understanding the host-viral interaction is an essential step in developing safe and effective anti-microbials against viruses. Since virus is most vulnerable at the early stage of lifecycle, this stage should therefore offer the best opportunity for therapeutic interventions. The early detection of invading viruses by the host depends on a limited number of Pattern Recognizing Receptors (PRRs) that serve as the primary intracellular sensors for viral specific genetic patterns and activate signal transduction cascades, thereby triggering interferon (IFN)-mediated antiviral defense mechanisms. Key virus-detecting PRRs include the nucleic acid-recognizing Toll-like receptors and the cytosolic RNA receptors RIG-I and MDA-5. Specifically, RIG-I has emerged as a key receptor in sensing viruses, including the influenza virus and hepatitis virus C (HCV), whereas MDA5 responds to the infection of picornaviruses and noroviruses. Upon viral infection, RIG-I undergoes the multiple step processes of ATP-dependent structural and functional activations to elicit IFN-mediated antiviral signal transduction. In addition, members of the tripartite motif (TRIM) proteins and the Linear Ubiquitination Assembly Complex (LUBAC) proteins also play major roles in the IFN-mediated inhibition of the lifecycles of viruses. Following the PRR-mediated viral sensing, hosts subsequently elicit intracellular



Total:64 page:(4/3)
32 Á¤º¸ ISBC (Àç)¹ÙÀÌ¿ÀÇÕ¼º¿¬±¸´Ü ¿¬±¸Áö¿øº»ºÎÀå ä¿ë Àç°ø.. 16.11.04 6141
31 Á¤º¸ ISBC (Àç)¹ÙÀÌ¿ÀÇÕ¼º¿¬±¸´Ü ¿¬±¸Áö¿øº»ºÎÀå ä¿ë °ø°í 16.10.17 6579
30 Á¤º¸ biodesig (Àç)¹ÙÀÌ¿ÀÇÕ¼º¿¬±¸´Ü ¼º°úÀü½Ãȸ¿¡ ÃÊ´ë ÇÕ´Ï´Ù 16.06.10 8185
29 Á¤º¸ biodesig (Àç)¹ÙÀÌ¿ÀÇÕ¼º ¿¬±¸´Ü ¿¬±¸¿ø ¸ðÁý °ø°í 16.02.22 7732
28 Á¤º¸ ISBC [Ãʺù°ø°í] Áö´ÉÇü ¹ÙÀÌ¿À½Ã½ºÅÛ ¼³°è ¹× ÇÕ¼º ¿¬.. 16.01.26 7173
27 Á¤º¸ ISBC [½Å±Ô°úÁ¦] Áö´ÉÇü ¹ÙÀÌ¿À½Ã½ºÅÛ ¼³°è ¹× ÇÕ¼º ¿¬.. 15.06.23 8140
26 Á¤º¸ ISBC ¿¬±¸´Ü ¿¬±¸¿ø ä¿ë ÀÔ»çÁö¿ø¼­ 15.06.22 6625
25 Á¤º¸ ISBC (Àç)¹ÙÀÌ¿ÀÇÕ¼º¿¬±¸´Ü ¿¬±¸¿ø »ó½Ãä¿ë °ø°í 14.09.19 7910
24 Á¤º¸ ISBC (Àç)¹ÙÀÌ¿ÀÇÕ¼º ¿¬±¸´Ü ¿¬±¸¿ø ¸ðÁý °ø°í 14.09.11 6902
23 Á¤º¸ ISBC (Àç)¹ÙÀÌ¿ÀÇÕ¼º ¿¬±¸´Ü ¿¬±¸¿ø ¸ðÁý °ø°í 14.08.08 6654
22 Á¤º¸ ISBC [½Å±Ô°úÁ¦°ø°í] (Àç)¹ÙÀÌ¿ÀÇÕ¼º¿¬±¸´Ü 2´Ü°è 2Â÷.. 14.07.10 5959
21 Á¤º¸ ISBC [Á÷¿ø°ø°í] (Àç)¹ÙÀÌ¿ÀÇÕ¼º¿¬±¸´Ü ¿¬±¸¿ø ¸ðÁý °ø.. 14.04.22 6715
20 Á¤º¸ ISBC [Á÷¿ø°ø°í] (Àç)¹ÙÀÌ¿ÀÇÕ¼º¿¬±¸´Ü Á÷¿ø ¸ðÁý °ø°í 14.04.18 7236
19 Á¤º¸ biodesig [¹ÙÀÌ¿ÀÇÕ¼º¿¬±¸´Ü] Áß°£Á¡°Ë ¿öÅ©¼ó ¾È³» 14.03.04 6833
18 Á¤º¸ ISBC 2013 EEWS, ISBC, and KIB Joint Symposium on Sy.. 13.10.07 8837
17 Á¤º¸ ISBC [Á÷¿ø°ø°í] (Àç)¹ÙÀÌ¿ÀÇÕ¼º¿¬±¸´Ü Á÷¿ø ¸ðÁý °ø°í 13.07.25 6135
[1] [2] [3] [4]